Compounded vs FDA-approved GLP-1s in 2026

Compounded GLP-1 medications are versions of semaglutide or tirzepatide prepared by compounding pharmacies rather than manufactured by the original drug makers. They became widely available during the GLP-1 drug shortages of 2023 and 2024, when demand for Ozempic, Wegovy, Mounjaro, and Zepbound far outpaced supply. For many patients, compounded products were the only way to start or continue treatment.

That landscape has shifted. The shortages that legally justified most compounding have ended, the FDA has escalated enforcement to a degree not seen in prior years, and manufacturer savings programs have narrowed the cost gap that drove many patients to compounding in the first place. At the same time, compounded GLP-1s remain available and widely marketed, often through the same telehealth channels that prescribe FDA-approved versions.

This article walks through what has changed, what the regulatory and safety differences actually are, how costs compare in 2026, and what questions are worth raising with a clinician before making a decision.

The FDA's position is straightforward: compounded GLP-1 products used for weight loss are not FDA-approved, which means the agency has not reviewed them for safety, effectiveness, or quality in the same way it reviews approved drugs. That distinction matters because patients often encounter compounded offerings through the same digital marketing channels as branded care, even though the regulatory posture is materially different.

On February 6, 2026, the FDA issued a formal intent-to-act statement signaling that it would move against non-FDA-approved GLP-1 products. On March 3, 2026, the agency followed through: it announced 30 warning letters in a single day targeting telehealth companies and compounding pharmacies for illegal marketing of compounded GLP-1s. That was the largest single-day enforcement action the FDA had taken in this category.

Across two enforcement waves, the FDA has issued more than 50 warning letters. The violations cited were specific: false equivalence claims suggesting compounded products are interchangeable with FDA-approved drugs, private-label branding designed to mimic brand-name packaging, dosing errors in product labeling, and questionable sourcing of active pharmaceutical ingredients. The enforcement pattern suggests the agency is treating this not as a marginal compliance issue but as a public health priority.

During the shortages of 2023 and 2024, compounding pharmacies operated in a recognized legal space. Under federal law, when an FDA-approved drug is on the official shortage list, compounders may prepare copies of that drug to fill the gap. This is not a loophole; it is an explicit provision in the Federal Food, Drug, and Cosmetic Act intended to protect patient access during supply disruptions.

That legal basis has largely disappeared. The FDA removed tirzepatide from the drug shortage list on December 19, 2024, and removed semaglutide on February 21, 2025. Once a drug is no longer listed as in shortage, the legal framework that permitted compounding of essentially identical copies tightens considerably, particularly for 503A pharmacies.

Some starter doses remain intermittently scarce, and individual patients may still encounter supply issues depending on geography and pharmacy. But the broad, category-wide shortages that defined the previous two years are over. The regulatory environment has shifted from tolerance to active enforcement, and patients relying on compounded products should understand that the legal footing beneath those products has changed.

Not all compounding pharmacies operate under the same rules. Federal law distinguishes between two categories, and the difference is significant for patients trying to evaluate the product they are receiving.

503A pharmacies

These are traditional compounding pharmacies that prepare medications for individual patients based on a specific prescription. They are regulated primarily by state pharmacy boards, not directly by the FDA. They are not required to follow current Good Manufacturing Practice (cGMP) standards, and they are not required to report adverse events to the FDA. Their distribution is limited and intended to be patient-specific.

503B outsourcing facilities

These are FDA-registered facilities that may compound medications in larger quantities without patient-specific prescriptions. They are regulated directly by the FDA, are required to follow cGMP standards, must report adverse events, and are subject to FDA inspection. They operate under a more rigorous oversight framework than 503A pharmacies.

Post-shortage rules

After a drug is removed from the shortage list, 503A pharmacies generally cannot compound products that are "essentially a copy" of a commercially available drug. 503B facilities face additional scrutiny as well, though the regulatory pathway is somewhat different. In practice, this means the legal basis for compounding GLP-1s has narrowed for both categories, but more sharply for 503A operations.

| Feature | 503A pharmacy | 503B outsourcing facility | |---|---|---| | Prescription required | Yes, patient-specific | No | | Primary regulator | State pharmacy board | FDA | | cGMP required | No | Yes | | Adverse event reporting | Not required | Required | | Bulk compounding permitted | No | Yes | | FDA inspection | Not routine | Yes, routine | | Post-shortage compounding of commercial drugs | Generally prohibited | Subject to FDA enforcement discretion |

The FDA has documented specific safety problems with compounded GLP-1 products, and the data are worth reviewing in detail rather than in summary.

Dosing errors are the most frequently cited concern. Compounded injectables have been associated with patients administering 5 to 20 times the intended dose due to confusion between milligrams, milliliters, and units. FDA-approved products use fixed-dose pen injectors that largely eliminate this risk. Compounded products are typically supplied in multi-dose vials that require the patient to draw the correct volume, a process that introduces meaningful room for error.

As of July 2025, the FDA had received 605 adverse-event reports associated with compounded GLP-1 products. Reported events include severe nausea, hypoglycemia, fainting, acute pancreatitis, and gallstones. Whether these events occurred at rates higher than those seen with FDA-approved versions is difficult to determine, because adverse-event reporting for compounded drugs is not systematically required.

Quality failures have also been documented. FDA testing of compounded products has identified samples containing impurities, samples with inconsistent doses across vials from the same batch, and in some cases products with no detectable active semaglutide at all. These findings are not representative of all compounding pharmacies, but they illustrate the quality variance that exists without cGMP requirements and routine FDA inspection.

One additional consideration: semaglutide has a half-life of approximately one week. If a dosing error results in a significant overdose, the effects are not brief. Symptoms from an excessive dose may persist for days, and there is no reversal agent.

Cost has been the primary driver of patient interest in compounded GLP-1s. The price difference is real, but it is smaller than many patients assume once savings programs are factored in.

| Option | Approximate monthly cost | |---|---| | FDA-approved (list price) | $935 -- $1,350 | | FDA-approved + manufacturer savings card | $0 -- $25 (commercial insurance) | | FDA-approved via telehealth program | ~$499 | | Compounded injectable | $179 -- $299 |

For patients with commercial insurance, manufacturer copay cards from Novo Nordisk and Eli Lilly can reduce out-of-pocket costs for FDA-approved products to $0 to $25 per month. In many cases, this makes the FDA-approved product cheaper than the compounded alternative.

Medicare Part D coverage for GLP-1 medications prescribed for obesity began in January 2026, with a monthly copay cap of $50 under the Inflation Reduction Act provisions. Patients covered by Medicare, Medicaid, or TRICARE are not eligible for manufacturer savings cards, which means the cost calculus is different for those populations.

The cost comparison is not static. Savings program terms change, compounding pharmacy prices vary, and insurance coverage rules shift from year to year. The relevant question is not what the general price range is, but what a specific patient would actually pay under their specific coverage situation.

The real question is not simply branded versus compounded. It is whether the patient understands what oversight exists, what the formulation claims are, and how that product is being marketed to them.

Cost is part of that decision, but it is not the whole picture. A patient paying $250 per month for a compounded product that could be obtained for $25 through a manufacturer savings card is not saving money. A patient without commercial insurance who cannot access savings programs faces a genuinely different set of options. The decision depends on the individual's coverage, eligibility, and clinical situation.

Regulatory status matters because it determines what quality assurance exists. An FDA-approved product has been tested for potency, purity, sterility, and stability under defined conditions. A compounded product may meet those standards, but no external process guarantees that it does unless the pharmacy is a 503B facility operating under cGMP with FDA inspection.

Clinical continuity also matters. Switching between compounded and FDA-approved formulations, or between compounding pharmacies, can introduce variability in dose, formulation, and response. Patients who have stabilized on an FDA-approved product and are considering switching to a compounded version for cost reasons should discuss the clinical implications with their prescriber.

This is also why provider behavior matters. If a clinic makes aggressive promises, glosses over approval status, or treats sourcing details like a footnote, that is itself a signal worth weighing.

If a patient and their clinician decide that a compounded GLP-1 is the appropriate choice, the quality of the pharmacy matters. Not all compounding operations are equivalent, and patients can take specific steps to evaluate what they are receiving.

Confirm that the pharmacy holds a current license from its state pharmacy board.

Look for accreditation from NABP (National Association of Boards of Pharmacy) or PCAB (Pharmacy Compounding Accreditation Board). Both are searchable at nabp.pharmacy.

Confirm whether the pharmacy is a 503A or 503B facility. If it is a 503B outsourcing facility, it should appear in the FDA's registry of outsourcing facilities.

Request a Certificate of Analysis for the specific product. This should include identity verification of the active ingredient, potency testing, sterility testing, endotoxin testing, and a beyond-use date.

Verify that the active pharmaceutical ingredient comes from an FDA-registered supplier. The pharmacy should be able to provide this information on request.

Watch for red flags: no publicly available licensing or inspection information, missing beyond-use dates on the product, vague or undisclosed ingredient sourcing, and unclear or evasive answers about whether the operation is 503A or 503B.

A pharmacy that is transparent about its regulatory status, testing protocols, and ingredient sourcing is more likely to be operating within established quality standards. A pharmacy that is not transparent about those things is telling you something.

Decisions about compounded versus FDA-approved GLP-1 medications should be made with a prescriber who understands the regulatory landscape and the patient's individual situation. The following questions are worth raising directly.

Am I eligible for a manufacturer savings card or patient assistance program?

Many patients do not know these programs exist or assume they do not qualify. Your prescriber or their office staff can often help determine eligibility and initiate the application.

What is the actual source and formulation of the compounded product being recommended?

Not all compounded semaglutide or tirzepatide is the same. The source of the active ingredient, the salt form used, the concentration, and the beyond-use dating all vary. Your prescriber should be able to explain what you are being prescribed and why.

What are the dosing instructions, and how do I avoid a dosing error?

If you are using a compounded vial-and-syringe product rather than a fixed-dose pen, ask your prescriber to walk through the draw-up process in detail and confirm the correct volume for your dose.

Is there a clinical reason to prefer one formulation over the other?

In some cases, a compounded formulation may offer a dose or concentration not currently available in the FDA-approved product line. In other cases, there is no clinical advantage. Your prescriber can help make that distinction.

What monitoring should be in place regardless of which product I use?

Side-effect monitoring, metabolic marker tracking, and dose titration schedules should not change based on whether the product is compounded or FDA-approved. If anything, monitoring may be more important with a compounded product where dose consistency is less assured.

What is the plan if the compounded product becomes unavailable or enforcement affects my pharmacy?

Given the current regulatory environment, patients using compounded GLP-1s should have a contingency plan. This might include identifying an FDA-approved alternative, confirming insurance coverage, or applying for a savings program in advance.